epm301 Dr Mechoulam
Dr Raphael Mechoulam is one of the most famous doctors in the world, especially in the world of cannabis medicine.
He was given the nickname “Father of THC” and the “father of cannabis research” as he is credited with discovering tetrahydrocannabinol and isolating it. With his groundbreaking discoveries, he has helped kick-start the medical cannabis revolution while helping thousands of people around the world. Over the past few years, he has made some significant achievements, although one of the latest came last year.
Dr. Mechoulam’s latest discovery is called EPM301or cannabidiolic acid methyl ester, also known as CBDa. EPM stands for Endless Potential Molecules, and there are now around 14 patented molecules being tested on humans with guidance from the US FDA.
What is the EPM301?
THC, CBD and other cannabinoids are considered secondary compounds in the cannabis plant because they are only produced after the primary acids are decarboxylated. In contrast, EPM301 is easily reproducible and has significant potential in the treatment of many inflammatory conditions.
Dr Mechoulam unveiled in 2019, but at the time it couldn’t be used in a pharmaceutical setting because it was naturally unstable, so he worked with EPM to find a way to make it more stable.
Swisa said Israel21c.org that the cannabinoids found in cannabis products these days are only found in dried cannabis flowers, while the living plant is where you can find the precursor acids of these cannabinoids. Cannabinoid acids themselves are more potent and just as promising as conventional medicine, although when exposed to heat they break down easily because they are so unstable.
“EPM asked, is it possible to create cannabinoid acids in the lab in a way that is stable and suitable for prescription drug development? This is the main difference between EPM and what is happening in the market today,” Swisa said.
“It is much smarter to use synthetic molecules because they are highly reproducible and because producing small molecules would cost less than creating plants. You can achieve scalability, reproducibility and robustness,” explained Prof. Dan Peer, director of Tel Aviv University’s Precision Nanomedicine Laboratory, who is also on the EPM Scientific Advisory Board.
Peer disclosed excellent results from a study of EPM301 for the treatment of IBD at the International Cannabis Conference held virtually in Israel in June 2021. “My lab investigated new approaches to treat diseases inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis,” he said. Israel21c. “I’m a very skeptical guy. Usually the molecules don’t work at the animal level let alone at the clinical level,” he said.
“But when I was approached four years ago by Raphael Mechoulam to check out some molecules he was synthesizing, we discovered that one of them – EPM301 – had unique super anti-inflammatory properties,” said said Peer. “It appears very safe in animal models and is much better than steroids which are the gold standard treatment for flare-ups. This could change the landscape of anti-inflammatory drugs.
Forbes shares more about the achievements of Dr. Mechoulam and EPM CEO Reshef Swisa.
“EPM has developed a method to work with the original substances of cannabis”, explains Dr. Mechoulam. “So while everyone is talking about THC and CBD, these cannabinoids are actually a secondary substance; they only appear later in the plant.
“Originally there is an acid that appears in the plant, and these acids are the mysterious worlds of compounds that are much more potent than cannabinoids,” he says. What makes Dr. Mechoulam’s discovery significant is that while cannabidiolic acids were previously known, they could not be used by pharmaceutical industries. Now they have found a way to modify the acids that would stabilize them enough to be used for pharmaceutical purposes.
“We took a cannabidiolic acid and stabilized it through a simple chemical procedure called esterification; then the compound is stable,” Swisa said.
“We badly need new drugs for several diseases and some of the available drugs may be good enough, but they end up causing side effects,” Dr. said. to be replaced: these are steroids and opioids.We believe that cannabis has the ability to introduce substitutes into these families.
Since EPM is patented, it proves that cannabinoids can be used as an effective substitute for opioids and steroids, especially when patients need to get rid of prescription drug addiction. “We are comparing our compound not only to cannabinoids, but to existing drugs that are applied today,” Dr. said. “So, for example, in IBD, we compared our compounds to two conventional products: one is prednisone (the steroids) and the other is a biologic drug, and in both cases we managed to prove that the activity of our compound is very similar to the common one.
“I sincerely hope that one day in the next few years we will have a cannabidiolic acid derivative on the market alongside CBD itself.” He also stressed the importance of drug regulation and classification to reduce the risk of side effects. “Companies need to be careful when taking compounds and claiming therapeutics. They have to do it according to the regulations in order to create consistency in the language…because people confuse recreational use with medical use and are not necessarily looking for a specific indication, with a specific dosage,” he said.
NEW CANNABINOID RESEARCH, READ THIS..
#Meet #EPM301 #Raphael #Mechoulams #Latest #Discovery #Potent #THC #CBD